
Can-Fite BioPharma Ltd. EPS Ratio | CANF
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Can-Fite BioPharma Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.97 | -10.9 | -17.9 | -0.01 | -0.03 | -0.04 | -0.14 | -0.17 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.01 | -17.9 | -4.39 |
Quarterly EPS Ratio Can-Fite BioPharma Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.97 | - | -10.9 | - | -17.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.97 | -17.9 | -11.6 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Champions Oncology
CSBR
|
-0.08 | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
-0.0846 | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
-0.47 | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
0.02 | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
-0.23 | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
7.3 | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
-7.26 | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
-0.26 | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
7.21 | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
0.62 | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
-0.34 | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
-0.74 | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
-0.13 | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
0.051 | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-3.03 | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
122 | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
-0.75 | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
0.23 | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
-0.8 | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
1.41 | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
-0.24 | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
8.58 | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
-0.32 | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
-0.68 | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
-2.43 | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
-2.26 | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
6.59 | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
-1.86 | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
67.9 | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
43.1 | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
-1.41 | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
27 | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
-0.01 | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
-3.31 | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
-3.81 | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
-0.3 | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
-2.97 | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
1.37 | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
-0.09 | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
-0.12 | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
-1.8 | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
0.8 | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
-7.12 | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
1.79 | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
-0.39 | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
0.39 | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
1.34 | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
2.32 | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
-4.04 | $ 1.6 | -8.86 % | $ 13.8 M |